Net margin is calculated as Net Income divided by its Revenue. ADMA Biologics's Net Income for the
three
months ended in Mar. 2026 was $45.3 Mil. ADMA Biologics's Revenue for the
three
months ended in Mar. 2026 was $114.5 Mil. Therefore, ADMA Biologics's net margin for the quarter that ended in Mar. 2026 was 39.59%.
The historical rank and industry rank for ADMA Biologics's Net Margin % or its related term are showing as below:
ADMA'
s Net Margin % Range Over the Past 10 Years
Min: -387.07 Med: -126.51 Max: 46.35
Current: 32.43
ADMA's Net Margin % is ranked better than 91.37% of 939
companies
in the Biotechnology industry
Industry Median: -88.29
vs ADMA: 32.43
ADMA Biologics (NAS:ADMA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ADMA Biologics Net Margin % Related Terms
ADMA Biologics Net Margin % Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Net Margin % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Net Margin % of 39.59% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #81 out of 939 companies in the Biotechnology industry, placing it in the top 8.6%.
Is ADMA Biologics' Net Margin % too high?
ADMA Biologics' current Net Margin % is 39.59%. Based on the distribution chart, ADMA Biologics ranks #81 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Net Margin % compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #81 out of 939 companies for Net Margin %. This places ADMA Biologics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Net Margin % is 39.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.05, compared to a current price of $9.11 — trading 49.6% below its estimated fair value. The current Net Margin % is 39.59%. ADMA Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Net Margin % is 39.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.11 is trading 49.6% below its estimated GF Value™ of $18.05.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Net Margin %: 39.59%
GF Value™: $18.05 vs. price of $9.11 (49.6% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
68GF Score
Get the complete analysis for ADMA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
